A Prospective, Multicenter, Single-Arm Objective Performance Criteria Clinical Trial Evaluating the Safety and Efficacy of a Single-Use Neurovascular Intravascular Shockwave Catheter and Intravascular Shockwave Therapy Device for Pretreatment of Calcified Lesions in the Extracranial Carotid Artery (CREATE Trial)) (Extended Follow-Up)

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Design: Prospective, multicenter, single-arm study with an extended follow-up period. Sample Size: 204 participants (based on the final number of cases enrolled in the registration trial). Endpoints: Primary: Surgical success rate (residual stenosis \<30% after stenting). Secondary: Target lesion re-narrowing rate, target lesion revascularization rate, MAE rate, ipsilateral stroke rate, and MACCE rate at 3 and 6 months postoperatively. Follow-Up: Participants will be followed up at 3 months ±15 days and 6 months ±30 days postoperatively. Inclusion criteria: All patients participating in this extended follow-up period are sourced from the registered clinical trial. Ethics and Consent: The trial will be conducted in accordance with the Helsinki Declaration and Chinese regulations. Informed consent will be obtained from all participants or their legal guardians. Sponsor: Shanghai Lanfan Boyuan Medical Technology Co., Ltd. Principal Investigator: Professor Huo Xiaochuan, Beijing Anzhen Hospital.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

• All patients participating in this extended follow-up period are sourced from the registered clinical trial.

Locations
Other Locations
China
Beijing Anzhen Hospital
RECRUITING
Beijing
Contact Information
Primary
Xiaochuan Huo
huoxiaochuan@126.com
010-64412431
Time Frame
Start Date: 2025-05-12
Estimated Completion Date: 2027-12-30
Participants
Target number of participants: 204
Treatments
Calcified Carotid Artery Stenosis Treated with IVL and Carotid Artery Stenting (CAS)
All patients participating in this extended follow-up period are sourced from the registered clinical trial.
Sponsors
Leads: Shanghai Bluesail Boyuan Medical Technology Co., Ltd.

This content was sourced from clinicaltrials.gov

Similar Clinical Trials